基于肽的抑制剂作为抗冠状病毒的广谱药物具有巨大潜力。
Peptide-based inhibitors hold great promise as the broad-spectrum agents against coronavirus.
作者信息
Tang Mingxing, Zhang Xin, Huang Yanhong, Cheng Wenxiang, Qu Jing, Gui Shuiqing, Li Liang, Li Shuo
机构信息
Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
Department of Otolaryngology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, China.
出版信息
Front Microbiol. 2023 Jan 19;13:1093646. doi: 10.3389/fmicb.2022.1093646. eCollection 2022.
Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome (MERS), and the recent SARS-CoV-2 are lethal coronaviruses (CoVs) that have caused dreadful epidemic or pandemic in a large region or globally. Infections of human respiratory systems and other important organs by these pathogenic viruses often results in high rates of morbidity and mortality. Efficient anti-viral drugs are needed. Herein, we firstly take SARS-CoV-2 as an example to present the molecular mechanism of CoV infection cycle, including the receptor binding, viral entry, intracellular replication, virion assembly, and release. Then according to their mode of action, we provide a summary of anti-viral peptides that have been reported in peer-reviewed publications. Even though CoVs can rapidly evolve to gain resistance to the conventional small molecule drugs, peptide-based inhibitors targeting various steps of CoV lifecycle remain a promising approach. Peptides can be continuously modified to improve their antiviral efficacy and spectrum along with the emergence of new viral variants.
严重急性呼吸综合征冠状病毒(SARS-CoV)、中东呼吸综合征冠状病毒(MERS)以及最近的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)都是致死性冠状病毒,它们在大片区域或全球范围内引发了可怕的流行病或大流行。这些致病性病毒感染人类呼吸系统和其他重要器官往往导致高发病率和高死亡率。因此需要有效的抗病毒药物。在此,我们首先以SARS-CoV-2为例,阐述冠状病毒感染周期的分子机制,包括受体结合、病毒进入、细胞内复制、病毒粒子组装和释放。然后根据其作用方式,总结了同行评审出版物中报道的抗病毒肽。尽管冠状病毒可以迅速进化以获得对传统小分子药物的抗性,但针对冠状病毒生命周期各个步骤的基于肽的抑制剂仍然是一种有前景的方法。随着新病毒变种的出现,可以不断修饰肽以提高其抗病毒效力和抗病毒谱。